Jevtana Articles
BioTrends views Xeljanz and Zytiga prescribing in USA
26 March 2013
Some advantages seen for Sanofi’s Jevtana by Germany’s IQWiG
25 January 2012
Zytiga overtaking Provenge in MCRPC
17 January 2012
Negative NICE guidance for Sanofi prostate cancer drug
12 January 2012
UK NICE negative on Sanofi’s Jevtana and GSK’s Benlysta but positive on ALK-Abello’s Pharmalgen
30 September 2011
Sanofi debuts prostate cancer drug Jevtana in UK
5 July 2011
EMA advisory committee backs Gilenya, Halaven, Jevtana, Pravafenix and Trobalt, but negatives for Fampyra and Multaq
24 January 2011
US FDA approves second new treatment for advanced prostate cancer, Sanofi-Aventis’ Jevtana
18 June 2010
Showing 1-11 of 11 articles
- 1
- FDA probes two deaths possibly linked to Lilly's antipsychotic Zyprexa Relprevv
- Negative US patent ruling for Novo Nordisk on Prandin
- Aspen Pharma offers to buy GlaxoSmithKline's thrombosis brands and manufacturing site
- US Supreme Court says patent settlement can "sometimes" be illegal
- Daiichi Sankyo files for Japanese approval of Prasugrel
